Treatment response and drug survival were similar in patients with ankylosing spondylitis (AS) and nonradiographic axial spondylarthritis (nr-axSpA) after initiation with tumor necrosis factor-α inhibitor (TNFi), according to a study of 263 patients with AS and 98 patients with nr-axSpA. Researchers found:
• Patients with AS were more often men (65.02% vs 45.92%) and had longer symptom duration (11.71 vs 7.34 years).
• Median levels of acute-phase reactant were significantly higher in patients with AS.
• Median BASDAI scores at initiation of TNFi therapy were not higher in patients with nr-axSpA than in patients with AS.
• BASDAI 20 and BASDAI 50 response rates at 12 months were not statistically different between groups.
• No statistically significant survival differences were seen between groups.
Citation: Corli J, Flipo RM, Phillipe P, et al. Tumor necrosis factor-α inhibition in ankylosing spondylitis and nonradiographic axial spondyloarthritis: treatment response, drug survival, and patient outcome. [Published online ahead of print November 15, 2015]. J Rheumatol. doi: 10.3899/jrheum.150372.